Surrozen Inc (SRZN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$22.76+0.98%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SRZN
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Advance clinical development by submitting IND for SZN-8141 and initiating Phase 1b/2a DUET study in diabetic macular edema by end of 2026.
Stated as a priority in 2 of last 2 quarters. Management is on track to submit the IND application for SZN-8141 in the second half of 2026 and initiate the DUET Phase 1b/2a study by year-end 2026. Cash and cash equivalents were $106.9 million at 2026-Q1 and $102.0 million at 2026-Q2, supporting ongoing development. The trajectory matches management's stated timeline and funding commitment.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Expect to submit IND application for SZN-8141 by end of Q3 2026 and initiate DUET Phase 1b/2a study by year-end 2026.”
“On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026.”
Progress development of lead candidates SZN-8141 and SZN-8143 for retinal diseases including diabetic macular edema and wet AMD.
Stated as a priority in 2 of last 2 quarters. Management highlighted progress on SZN-8141 and SZN-8143 for retinal diseases with preclinical data and clinical plans. While revenue from collaboration milestones was $5.0 million in both 2026-Q1 and 2026-Q2, net losses remain significant, reflecting ongoing investment. The trajectory shows continued advancement consistent with management's stated focus.
“The Company continues to advance its ophthalmology pipeline (SZN-8141 and SZN-8143) targeting retinal diseases.”
“Surrozen remains focused on advancing a new generation of ophthalmology therapeutics built on Wnt pathway biology.”
Collaborate with Boehringer Ingelheim on development of SZN-413 for retinal diseases, including milestone achievements and license revenue.
Stated as a priority in 2 of last 2 quarters. Management reported milestone payments of $5.0 million in both 2026-Q1 and 2026-Q2 from Boehringer Ingelheim under the SZN-413 collaboration. This revenue reflects active partnership progress. The trajectory shows consistent milestone achievements aligned with management's partnership strategy.
“Boehringer Ingelheim achieved a development milestone under the SZN-413 license agreement in June 2026.”
“Received $5.0 million payment from Boehringer Ingelheim in April 2026 for milestone under collaboration agreement.”
Preserve cash and cash equivalents above $100 million to fund ongoing R&D and operational expenses.
Stated as a priority in 2 of last 2 quarters. Cash and cash equivalents were $106.9 million at 2026-Q1 and $102.0 million at 2026-Q2, showing a slight decline but maintaining a strong cash position to support operations. The trajectory is consistent with management's commitment to capital preservation.
“Cash and cash equivalents were $102.0 million as of June 30, 2026.”
“Cash and cash equivalents were $106.9 million as of March 31, 2026.”
Over the trailing year it converted 0.22x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
8 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.